inhibitor

Chmiel et al., "Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis," Journal of Cystic Fibrosis, vol.

Expression and secretion of alpha1-proteinase inhibitor are regulated by proinflammatory cytokines in human pancreatic islet cells.

to support research into alpha1-antitrypsin deficiency, a genetic condition in which low levels of the essential blood protein alpha1-proteinase inhibitor, can cause emphysema.

Kamada's proprietary alpha-1 antitrypsin therapy is the first available ready-to-infuse liquid alpha1-proteinase inhibitor (Alpha1-PI) and is indicated as a chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe congenital AAT deficiency.

GLASSIA, the first and only liquid alpha1-proteinase inhibitor in the US, Australia, New Zealand and Canada, was approved by the US FDA on 1 July 2010 and is indicated for chronic augmentation and maintenance therapy in individuals with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (Alpha1-PI), also known as alpha1-antitrypsin (AAT) deficiency.